SCHEMBL6984032

SCHEMBL6984032

CN(C)CCCCCCCCNC=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 3/20 0.56
ADH1A P07327 3/20 0.56
ADH7 P40394 3/20 0.56
ADH1C P00326 2/20 0.56
EPHX1 P07099 1/20 0.56
ADH4 P08319 1/20 0.56
ALDH1A1 P00352 1/20 0.52
TSHR P16473 1/20 0.52
PAOX Q6QHF9 1/20 0.47
KDM4E B2RXH2 2/20 0.46
DNM1 Q05193 3/20 0.44
TDP1 Q9NUW8 1/20 0.41
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4A O75164 6/20 0.37
KDM4C Q9H3R0 6/20 0.37
KDM5A P29375 1/20 0.37
KDM7A Q6ZMT4 1/20 0.37
PHF8 Q9UPP1 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6984194 1.00 ADH1B (0.56) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL7294488 1.00 ADH1B (0.56) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL1313601 0.98 ADH1B (0.54) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL93285 0.93
Hydrochloric Acid SCHEMBL4797793 0.91 ADH1B (0.52) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL10918505 0.85 ADH1B (0.46) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL93136 0.82
Hydrochloric Acid SCHEMBL3855665 0.80 ADH1B (0.48) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL11318180 0.80 ADH1B (0.56) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL6747424 0.79 ALDH1A1 (0.65) ALDH1A1TSHRPAOXKDM4EDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 ADH1B 1403/4885ADH1A 293/4885ADH7 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.